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Abstract:  
E2f transcription family encompasses a wide-range of functions in regulating cell 
proliferation, cell differentiation and apoptosis. The two recent additions to the E2F family, E2f7 
and E2f8, had unique structural features that set them apart from E2Fs. These structural features 
enabled these two E2Fs with the capacity for homo-dimerization and hetero-dimerization, and 
hence they can redundantly regulate downstream target like E2f1 and p53.  Unlike the function 
of other E2F members, E2F7 and E2F8’s biological function in mouse development was found 
crucial.  Simultaneous deletion of E2f7 and E2f8 induces ectopic E2F1-P53 dependent apoptosis 
in addition to vascular formation defect and placental deformation that eventually lead to early 
embryonic lethality at E11.5.  My work strongly suggests that functions of E2F7 and E2F8 in the 
extra-embryonic cell lineages are vital for embryos to survive until term.  I here show that 
preserving functional E2F7 and E2F8 in placental tissue allows fetuses deficient for E2f7 and 
E2f8 go to term, but these animals were still physiologically impaired and died soon after birth. 
The phenotype stemming from losses of E2f7 and E2f8 in mouse development mimicked that 
resulted from the loss of Rb, indicating that E2F7 and E2F8 can potentially mediate Rb in 
regulating cell-cycle progression and apoptosis during development and potentially during 
tumorgenesis.  
 
Introduction:  
The Retinoblastoma (Rb) gene was identified twenty years ago as the first tumor suppressor. 
It was initially identified by positional cloning due to its frequent loss-of-function mutation 
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found in pediatric eye tumors.  Aberrant signaling pathways and direct mutations of the Rb gene 
have been since linked to various tumorgenic processes in wild-ranges of tissue types (Harbour 
and Dean, 2007).  Besides its obvious function as a tumor suppressor, Rb’s biological function is 
required in mouse development.  The ablation of Rb in mice induces abnormal cellular activities 
and severe physiological defects that lead to embryonic lethality at E14.5.  Loss of Rb induced 
unscheduled trophoblast cell proliferation and destruction of placental labyrinth architecture that 
disrupts normal maternal-fetal transportation.  Furthermore, neurogenic defects were discovered 
in embryos lacking Rb.  These mutant embryos had massive ectopic cell cycle entry and elevated 
apoptosis in central nervous system and peripheral nervous system (Wenzel et al, 2007, de Bruin 
A. et al, 2003).  During embryonic developmental stages, Rb function was seen exceptionally 
important in the extra-embryonic compartment; deletion of Rb in these tissues alone was capable 
of inducing embryonic death (Wenzel et al, 2007, de Bruin A. et al, 2003).   
The Rb gene product, pRb, is a nuclear phosphoprotein that arrests cell cycle at the G1/S 
transition.  The tumor suppression function of Rb requires the central “pocket” domain that was 
most naturally targeted in tumor-promoting events. Sequences within such domain are required 
for the binding of Rb with endogenous proteins that regulate cell-cycle progression (Grana et al, 
1998).  During cell cycle, three different cyclin and cyclin-dependent kinase (cdk) complexes 
activate Rb signaling pathways by phosphorylation at specific sites of Rb.  Rb can also command 
cell cycle repression as an effector of cdk inhibitor and p53 (Harbour and Dean, 2007).  
In the Rb paradigm that has emerged in the last twenty years since its discovery, a family of 
transcription factors, the E2f transcription factors appeared to be an important group of 
downstream effectors, in vitro evidence has suggested that each performing distinct functions in 
regulating normal and tumorgenic cellular activities.  Phosphorylation of Rb during cell cycle 
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can release E2Fs from the Rb-E2F complexes to promote E2F-dependent transcriptions and 
subsequent cell-cycle progression (Harbour and Dean, 2007). The complexity of the Rb-E2f 
model was not restricted to the cell-cycle related regulation of Rb, since constitutive expression 
of Rb and its pocket proteins p130 and p107 recruits several E2fs and corepressors such as 
chromatin remodeling complexes to elicit multiple molecular responses which repress cell- 
proliferation (Grana et al, 1998).  
A large body of work suggests that E2Fs can function to activate and repress the 
transcription of many essential genes involved in cell proliferation, apoptosis and differentiation 
(Dimova, Dyson 2005).  The fact that E2F activity can be regulated during the cell cycle at 
multiple levels, including by direct binding of the Rb tumor suppressor, as well as by 
transcription, protein degradation and post-translational mechanisms suggests that cell cycle-
dependent regulation of E2F is critical for cellular homeostasis.  The effects of deregulated E2F 
activity are pleiotropic and vary in different experimental settings, either promoting cellular 
proliferation or cell death.  While a decrease in E2F activity is associated with a reduction in the 
proliferation capacity of cells, an increase in E2F activity is often associated with the induction 
of apoptosis.  Depending on the tissue examined, E2F-induced apoptosis can be p53-dependent 
or independent. More recent studies have begun to reveal specific roles of E2F family members 
in the control of proliferation and apoptosis. 
The mammalian E2F proteins are encoded by eight distinct genes (E2F1-8) and are 
believed to play a critical role in orchestrating the oscillatory pattern of cell cycle dependent 
gene expression.  Based on structure-function studies and amino acid sequence bioinformatics 
analysis, the E2F family can be conveniently divided into two general subclasses, transcription 
repressors and activators.  The repressor subclass consists of E2F3b, E2F4, E2F5, E2F6, E2F7 
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and E2F8.  With the exception of E2F7 and E2F8, this group is constitutively expressed during 
the cell cycle and serve to recruit Rb- related pocket proteins and a number of associated co-
repressor proteins to E2F-target promoters, resulting in their repression during G0 (Attwooll et al., 
2004).  As cells are stimulated to enter the cell cycle, cyclin dependent kinases phosphorylate 
pocket proteins, leading to the dissociation of E2F repressor complexes and the derepression of 
E2F-target genes.  The activator subclass, consisting of E2F1, E2F2 and E2F3a, are themselves 
repressed by E2F repressor complexes. Thus, cdk-dependent phosphorylation of pocket proteins 
leads to the accumulation of E2F1, E2F2 and E2F3a proteins late in G1.  These activators then 
transiently bind to E2F-binding elements on target promoters, resulting in their acute activation 
at the G1/S transition.  Consistent with an important function in regulating gene expression 
during G1/S, the over-expression of activators in quiescent cells can potently transactivate many 
of these G1/S regulated E2F-responsive genes.  The consequence of this regulation to cell 
proliferation was highlighted by the analysis of mouse embryonic fibroblasts (MEFs) deficient 
for E2F1, E2F2, and E2F3.  In these experiments, the acute loss of the three activator E2Fs 
resulted in a reduction of E2F target genes and a severe block in cell proliferation (Wu 2001).  
While a great deal is now understood about how E2F3b/4/5/6-mediated repression in G0 is 
coordinated with E2F1/2/3a-mediated activation in G1/S to regulate the induction of E2F targets 
as cells enter the cell cycle, little is known about how target genes are subsequently 
downregulated during S/G2 to complete the oscillation of gene expression observed during the 
cell cycle. 
E2F7 and E2F8 have unique features among the E2F family.  These novel E2Fs lack the 
leucine-zipper domain required for dimerization with the partner proteins DP1/2 (Figure 1).  In 
addition, E2F7 and E2F8 possess two DNA binding domains that allow them to function in a 
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DP-independent manner. The two separate domains exhibit high homology to the DNA binding 
domains of E2F, both of which are essential in binding to E2f  DNA consensus sequences.  In 
contrast to the rest of the E2F family, E2F7 and E2F8 are maximally expressed during S and G2 
phases of the cell cycle.  Together with their ability to repress gene expression and block cell 
proliferation in cultured cells, these observations suggest that E2F7 and E2F8 may represent as a 
unique arm of the E2F network. 
To investigate the physiological functions of E2F7 and E2F8 in vivo, the Leone Lab has 
used homologous recombination techniques to target the inactivation of E2f7 and E2f8 in mice.  I 
found that while single deletion has no effect on mouse development, the combined loss of E2f7 
or E2f8 results in the accumulation of E2F1 and p53, massive apoptosis throughout fetal tissues, 
and embryonic lethality by E11.5.  The execution of apoptosis in E2f7-/-E2f8-/- embryos was 
found to be E2F1 and p53 dependent.  These data define a role for E2F7 and E2F8 in embryonic 
cell survival via direct control of the E2F1-p53 axis.  While removing downstream effectors E2f1 
or p53 can relieve aberrant apoptosis in E2f7-/-E2f8-/- embryos, it cannot halt embryonic lethality 
caused by simultaneous loss of E2f7 and E2f8.  Surprisingly, only reconstitution of mutant 
fetuses with normal wild-type placentas can restore normal gestation, indicating that disruption 
E2f7 and E2f8 have deleterious consequences in placental development and embryo survival.  
 
Materials and methods 
Generation of E2f7 and E2f8 knockout mice 
PCR generated probes for E2F7 and E2F8 were used to screen a 129Sv/Ev bacterial artificial 
chromosome library.  A 7-kb XbaI fragment of E2F7 spanning exon 4 and 5 was isolated from 
RPCI 22 431 H17 and a 6.64-kb fragment of E2F8 containing exon 3 and 4 was isolated from 
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RPCI 22 539 P23.  To generate E2F7 and E2F8 targeting constructs, both fragments were first 
subcloned into pBluescript and subsequently engineered into pLoxPII (ref.) with flanking loxP 
sites and a neomycin cassette inserted in reverse orientation.  The pLoxPII targeting vector was 
linearized with NotI, and electroporated into TC1 129Sv/Ev embryonic stem (ES) cells (ref).  
Cells undergoing homologous recombination were selected by growth on G418 plus ganciclovir 
and verified by Southern blot using indicated probes.  Selected ES clones were injected into 
C57BL/6 blastocysts to generate chimaeric mice.  I bred the resulting chimaeric males with 
National Institute of Health (NIH) Black Swiss females to achieve germline transmission.  
Offspring were bred to EIIa-Cre mice to excise the neomycin cassette to produce conventional 
and conditional null mice.  Genotypic analysis of offspring was performed by Southern blot 
analysis and multiplex PCR using three primers: E2F7-a, 5’-AGGCAGCACACTTGACACG-3’; 
E2F7-b, 5’-ACTTTTGGGACAGAGGTAGGA-3’; E2F7-c, 5’-
CCAAGATGAAGGCCGAGATGCTAC-3’; or E2F8-a, 5’-TAAAAAGCTTTGCGGTCGTT-3’; 
E2F8-b, 5’-AAGCCAACCTCGATGAATTG-3’; E2F8-c, 5’-CTCGCATCATCGTCTGCTAA-
3’). 
 
Quantitative real-time PCR 
Total RNA was isolated using Qiagen RNA miniprep columns as described by the manufacturer, 
including the optional DNase treatment before elution from the column.  Reverse transcription of 
total RNA was performed using Superscript III reverse transcript reagents (Invitrogen) and 
RNAse Inhibitor (Roche) according to the manufacturer’s instruction.  Real-time RT-PCR was 
performed using the BioRad iCycler PCR machine. Reactions were done in triplicate and relative 
amounts of cDNA were normalized to GAPDH.  Primer sequences are available upon request. 
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Co-immunoprecipitation assay 
Human embryonic kidney HEK293 cells were cultured in DMEM medium supplemented with 
15% FBS and used for co-immunoprecipitation assay.  Transient transfections with indicated 
constructs were performed by standard calcium chloride technique.  Transiently transfected 
HEK293 cells were harvested in cold phosphate-buffered saline, and cell pelletes were lysed in 
10 times volume of lysis buffer (0.05M sodium phosphate PH7.3, 0.3M NaCl, 0.1% NP40, 10% 
glycerol with protease inhibitor cocktail).  Co-immunoprecipitation was performed as described.  
For analysis of protein interactions, Flag and/or HA tagged proteins were transfected as indicated 
in Figure 5.  Flag or HA antibody was used for the precipitation.  After extensive washing, 
proteins bound to affinity resins were resolved by SDS-PAGE and detected by Western blotting 
as indicated. 
 
Immuno-affinity Purification (IAP) 
E2F7 associated complexes were purified from Hela cells stably transduced with FLAG-HA 
tagged E2F7 (ref).  Nuclear extracts were prepared by modified Dignam prep in that nuclei 
pellets were extracted with Buffer C-450 (20mM HEPES, pH 7.9, 450 mM KCl, 1.5 mM MgCl2, 
25% glycerol, 0.2mM EDTA) equal to the nuclei pellet volume (ref).  Resulting extracts were 
incubated with pre-equilibrated FLAG M2 affinity resin (Sigma) for 3h.  Resin/extract mixtures 
were decanted onto Bio-Spin columns (BioRad) and allowed to empty by gravity.  After 3 
washes with 10 column volumes of Wash Buffer (20mM HEPES, pH 7.9; 150mM KCl; 10% 
glycerol; 0.2mM EDTA), complexes were eluted by incubation with Wash Buffer plus 
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200μg/mL of FLAG peptide (Sigma) for 1h, followed by a brief spin to collect the eluents.  The 
FLAG eluents were subsequently subjected to Western blot analysis using anti-E2F8 antibody.  
All nuclear extraction and immuno-affinity purification steps were done at 4˚C and fresh 
protease inhibitors were added to all working solutions.  .  Hela cells were transduced with 
retroviruses expressing a bicistronic mRNA encoding human E2F7 (Flag-HA-7) linked to an 
interleukin-2 receptor (IL-2R)-α as surface marker.  The transduced subpopulation was purified 
by affinity sorting (S).  Cells before and after sorting 
 
Chromatin immunoprecipitation (ChIP) and sequential ChIP assays 
For ChIP assay, the EZ CHIPTM assay kit (Upstate Biotech) was used as described by the 
manufacturer.  Briefly, harvested HEK293 cells overexpressing E2F7 and/or E2F8 were cross-
linked and chromatin was sonicated to an average size of 200-1000bp.  Lysates were 
subsequently pre-cleared with Salmon Sperm DNA/Protein G agarose slurry (Upstate).  Then 
antibodies specific to Flag, HA, or normal mouse IgG (Oncogene) were added to each sample 
and incubated overnight at 4o C.  Antibody-protein-DNA complexes were recovered by addition 
of 30 μl of Salmon Sperm DNA/Protein G agarose slurry and incubation for 1 hour at 4o C.  
Following extensive washing, the complexes were eluted and cross links were reversed by 
heating the samples to 65o C for 4 hours.  Finally, samples were treated with Proteinase K (Roche) 
and Rnase A (Roche) and purified through Qiaquick columns (Qiagen).  Real-time PCR was 
performed using the Biorad iCycler PCR machine with the specific primers of certain promoter 
regions.  Reactions were done in triplicate and normalized using the threshold cycle number for 
the total input sample.   
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Sequential ChIP-PCR was carried out using the same EZ CHIPTM protocol, except 
involving two rounds of chromatin immunoprecipitation steps.  The first round of 
immunoprecipitation was performed by incubation with M2 anti-FLAG antibody and Salmon 
Sperm DNA/Protein G agarose slurry.  Precipitated DNA-protein complexes were eluted by 1h 
incubation with Flag peptide (F3290, Sigma) at 4°C and then subjected to a second round of 
precipitation with primary antibodies as indicated in Figure 6c. After extensive washing, 
sequentially precipitated complexes were recovered by addition of 30 μl of Salmon Sperm 
DNA/Protein G agarose slurry and incubation for another 1h at 4o C.  Protein-DNA complexes 
collected from Sequential ChIP were treated and subjected to the real-time PCR analysis as 
described above for ChIP experiments.  Primer sequences are available upon request. 
 
Western blot and antibodies 
Immunoblotting analyses were done by standard procedure.  The following commercial 
antibodies were used as indicated in the figures: Caspase-3 (9662, Cell Signaling), p53 (Ab-1, 
Oncogene), E2F1 (C-20, Santa Cruz), Flag (M2, Sigma), E2F8 (M01, Abnova), HA (12C5A, 
Rocha), Myc (9E10, Santa Cruz). Primary antibody blotting was detected using appropriated 
horseradish-peroxidase-conjugated secondary antibodies and ECL reagent as described by the 
manufacturer (Amersham Biosciences). 
 
FACS analysis 
E2F7/8 knockout MEFs were synchronized by starvation in DMEM containing 0.2% FBS for 
48h and blocked at the G1/S transition by the addition of DMEM containing 15% FBS and 1mM 
hydroxyurea (HU) for 18h.  Cells were then washed 3 times with PBS and released into the cell 
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cycle by adding fresh medium containing 15% FBS.  Cells were harvested at the indicated time 
points and processed for flow cytometry, quantitive real-time PCR.  For FACS analysis cells 
were harvested by trypsinization, fixed in 70% ethanol and stained with propidium iodide using 
standard protocol. 
 
Cell culture, proliferation and viability assay 
E2F7 and E2F8 conditional knockout mouse embryonic fibroblasts (MEFs) were isolated from 
E13.5 embryos and maintained in DMEM medium containing 12.5% fetal bovine serum (FBS).  
Immortalized cell lines were generated from primary MEFs using standard 3T3 and 3T9 protocol.  
To obtain conventional DKO cells, I transfected immortalized MEFs with retrovirus expressing 
Cre recombinase using standard methods (ref.).  
 
Cell Growth Measurement  
To measure the proliferation rate of MEFs, 1x10^6 cells were seeded to 10mm cell culture dish 
(Corning) on the initial day of experiment.  Each following 24 hours, total cell numbers were 
assayed by trypan blue exclusion method, and all cells were re-seeded for similar analysis at 
succeeding time-points.  
 
BrdU and TUNEL asssays 
Pregnant females at 9.5 days postcoitum were injected intraperitoneally with BrdU (100 
ug/grams of body weight) 3 hours prior to harvesting.  Embryos were fixed in formalin upon 
harvesting and 5um paraffin embedded-sections were used for immunohistochemistry analysis 
after deparaffinization.  Anti-BrdU antibody (DAKO Co. MO-0744) and Vectastain Elite ABC 
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reagent (Vector labs) were used to detect BrdU incorporation according to the manufacturer’s 
instructions, followed by hematoxylin counterstaining.  Apoptotic cells were determined using 
TUNEL assay (Chemican S7101), according to the manufacturer’s protocol.  All slides were 
counterstained with hematoxylin.  Proliferation and apoptosis were measured by quantitation of 
the ratio between positive-signaling and total cells. 
 
Tissue processing and β-galactosidase staining assay 
Tissue was excised and portions were processed for in situ X-gal staining.  Tissue was fixed 
directly in paraformaldehyde (2% PFA/0.2% glutaraldehyde in a 100 mM sodium phosphate 
buffer, pH=7.4) for 2 to 2.5 hours at 4oC, washed for 10 min twice in phosphate-buffered saline 
(PBS) and then stained in a 5-bromo-4-chloro-3-indolyl-D-galactopyranoside (β-gal) solution [4 
mM potassium ferricyanide (Sigma), 4mM potassium ferrocyanide (Sigma), 2 mM magnesium 
chloride (Sigma), 0.2% IGEPAL CA-630 (NP-40 substitute, Sigma), 0.1% sodium deoxycholic 
acid (Calbiochem) and 1 mg/mL β-gal (Gold Bio Technology, St. Louis, MO) in PBS for 18 
hours at RT protected from light.  β -gal-stained tissue was washed for 10 min twice with PBS 
and post-fixed in 10% neutral-buffered formalin (Richard Allen) for 48 hrs at RT.   
 
 
Results 
E2F7 and E2F8 are essential for embryonic viability 
To investigate E2F7 and E2F8 functions in vivo, the Leone lab utilized cre-loxP technology to 
disrupt E2F7 and E2F8 function in mice.  Targeting of E2f7and E2f8 was achieved by flanking 
exon 4 in E2f7 and exon 3 and 4 in E2f8 with loxP sites using homologous recombination 
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techniques (Figure 2a).  In each case, exon 4 encodes essential sequences for specific DNA 
binding activity and ablation of loxP-flanked sequences is predicted to result in a shift of the 
open reading frames, leading to premature termination of translation.  Correct targeting of E2f7 
and E2f8 in ES cells was verified by Southern blot and PCR analysis (data not shown).  Correctly 
targeted ES clones were injected into C57BL/6 blastocysts and chimeric male mice were mated 
with Black Swiss females.  Agouti offspring with germline transmission of the targeted alleles 
were then bred with EIIA-cre mice.  Pups lacking either the neo cassette (conditional knockout 
alleles; E2f7loxP/+ and E2f8loxP/+) or both the neo cassette and the loxP-flanked regions of E2f7 or 
E2f8 (conventional knockout alleles; E2f7+/- and E2f8+/-) were identified by Southern blot and 
PCR genotyping analysis (Figure 2b).   
Intercrosses between E2f7+/- or E2f8+/- animals resulted in viable E2f7-/- and E2f8-/- 
offspring that appeared externally normal, were fertile and lived to old age.  Given the structural 
and functional similarities between E2F7 and E2F8 (ref), I investigated the possibility that these 
family members could compensate for the absence of the other.  Real-time PCR analysis of E2f7 
and E2f8 expression, however, revealed that their expression was unperturbed in single knockout 
embryos (Fig. 2c) or mouse embryo fibroblasts derived from embryos (data not shown), 
suggesting that compensation between these family members was not taking place in these 
animals, at least at the mRNA level.  To explore the possibility of functional redundancy 
between E2F7 and E2F8 I examined the biological consequence of ablating both.  To this end, I 
intercrossed E2f7+/-E2f8+/-, E2f7-/-E2f8+/- and E2f7+/-E2f8-/- animals and analyzed the resulting 
offspring.  Whereas E2f7-/-E2f8+/- and E2f7+/-E2f8-/- pups were found at the expected Mendelian 
ratios,  no E2f7-/-E2f8-/- double knockout (DKO) pups were found at birth (P0).  Analysis at 
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earlier stages of embryonic development revealed that only 50% of the DKO embryos were alive 
at embryonic day 10.5 (E10.5), and no DKO embryos were alive at E11.5 (Table 1).   
 
E2F7 and E2F8 form homo- and hetero-dimers  
Previous studies demonstrated an ability of E2F7 and E2F8 to form homodimers (Figure 3a, top 
panels; ref).  The fact that E2F7 and E2F8 are coexpressed in most cells of the embryo and 
appear to have overlapping functions in vivo led me to explore the possibility that E2F7 may 
physically interact with E2F8.  Because immunoprecipitation-quality antibodies for E2F7 and 
E2F8 are not yet available, my mentor Jing Li used HeLa cells expressing flag-hemagglutinin 
(HA) epitope tagged E2F7 to assess whether endogenous E2F8 could be found in complex with 
the doubly-tagged version of E2F7.  As shown in Figure 3b, sequential immunoprecipitations 
with anti- flag and anti- HA antibodies revealed a specific interaction between endogenous E2F8 
and flag-HA-E2F7.  Similarly, endogenous E2F7 could be found in association with flag-HA-
E2F8 (data not shown).  The interaction between E2F7 and E2F8 was confirmed by co-
immunoprecipitation assays using HK293 cells co-expressing flag-tagged E2F7 and HA-tagged 
E2F8 (Figure 3a).   
Given that E2F7 and E2F8 can form homodimers as well as heterodimers, I evaluated the 
preferred dimerization state in cells.  To this end, cells were co-transfected with flag-7, HA-7, 
and myc-8 or with flag-8, HA-7, and myc-8, and flag-immunoprecipitates were blotted with 
either anti-HA or anti-myc.  The immunoprecipitated E2F7 or E2F8 was quantified relative to 
1% of the input material.  As shown in Figure 3c, E2F7 had a greater binding affinity to itself 
than to E2F8.  On the other hand, E2F8 had a greater affinity for E2F7.  From this analysis I 
conclude that the preferred state of dimerization is E2F7:E2F7 > E2F7:E2F8 > E2F8:E2F8. 
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 E2f1 is a direct target of E2F7 and E2F8  
Chromatin immunoprecipitation (ChIP) assays were then used to assess the ability of E2F7 and 
E2F8 to bind known E2F target promoters.  HEK293 cells transiently transfected with a flag-
tagged E2F7 or E2F8 were cross-linked with formaldehyde, extracts were prepared, DNA was 
fragmented and the chromatin material was immunoprecipitated with antibodies specific for the 
flag epitope.  Quantitative real-time PCR assays designed to measure the enrichment of E2f1 
promoter or control tubulin promoter sequences in immunoprecipitated DNA show that E2F7 is 
specifically recruited to E2F binding sites on the E2f1 promoter (Figure 4d).  This recruitment 
was specific since IgG immunoprecipitates or anti-flag immunoprecipitates of flag-E2F7 DBD1 
mutant extracts failed to specifically amplify E2f1 promoter sequences.  Similarly, E2F8 could 
be specifically recruited to the E2f1 promoter (data not shown). 
I then addressed whether E2F7-E2F8 heterodimers could bind the E2f1 promoter.  To this 
end, HEK293 cells expressing HA-tagged E2F7 and Flag-tagged E2F8 were first 
immunoprecipitated with anti-flag antibody; immunopreciptated DNA-protein complexes were 
then eluted with excess flag peptide and reimmunoprecipitated with HA-specific antibodies.  The 
final immunoprecipiates were then similarly amplified with primers specific for the E2f1 or 
tubulin promoters.  These sequential ChIP assays show that E2F7 and E2F8 simultaneously 
occupy E2F binding sites on the E2f1 promoter (Figure 3e).  From these experiments, I conclude 
that E2F7 and E2F8 homodimers and heterodimers can be specifically recruited to the E2f1 
promoter.   
 
E2f1 expression is derepressed in E2f7-/-E2f8-/- MEFs. 
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To determine whether the recruitment of E2F7 and E2F8 to the E2f1 promoter has a functional 
consequence on its expression, I examined E2F1 protein and mRNA levels in E2f7-/-E2f8-/- MEFs.  
Western blot and real-time PCR assays showed a consistent increase of E2F1 protein and mRNA 
levels in DKO MEFs relative to wild type MEFs (Figure 4b and 4c), suggesting that E2F7 and 
E2F8 are required for the repression of E2f1.  This increase in E2f1 expression is likely due to 
transcriptional deregulation of its promoter since E2f1 luciferase promoter activity was similarly 
elevated in DKO cells.  Importantly, mutation of the E2F and CRH binding elements on the E2f1 
promoter resulted in a derepression of reporter activity in wild type but in DKO MEFs (Figure 
4d), suggesting that the regulation of E2f1 expression by E2F7 and E2F8 is direct. 
E2f7 and E2f8 expression fluctuates during the cell cycle, with maximal expression in S 
and G2; I hence evaluated E2f1 expression in DKO MEFs more closely at various stages of cell 
cycle progression.  To this end, wild type and DKO MEFs were synchronized by serum 
deprivation, followed by restimulation with medium containing 10% serum and 2mM 
hydroxyurea (HU).  Cells synchronized at G1/S were stimulated to enter S phase and to progress 
though the cell cycle by removing HU from the medium.  Cell cycle progression was monitored 
by flow cytometry (Figure 4e).  Cells harvested periodically were processed for RNA and protein 
and E2f1 expression at each time point was evaluated by real-time PCR and Western blot assays.  
As expected, E2f1 expression in wild type cells accumulated during G1/S and subsequently 
decreased during S and G2.  Strikingly, expression of E2f1 in DKO cells continued to increase as 
cells progressed through S and G2, accumulating upto 12-fold higher than in wild type cells 
(Figure 4f).  These data suggest an important role for E2F7 and E2F8 in repressing E2F-target 
expression during S and G2 phases of the cell cycle. 
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E2f7-/-E2f8-/- DKO cells proliferate normally but are hypersensitive to apoptosis in vitro  
Given the fact that E2f1 is unregulated in the E2F7-/-;E2F8-/- DKO cells and overexpression of 
E2F1 will lead to proliferation and apoptosis, I examined the effect of loss of E2F7 and E2F8 on 
proliferation and apoptosis using mouse embryonic fibroblasts (MEFs).  Since conventional 
E2F7-/-;E2F8-/- DKO embryos die during early mouse development, MEFs were isolated from 
conditional embryos at E13.5, and deletion of the floxed alleles was performed in vitro by 
infection with a retrovirus expressing the Cre recombinase.  Proliferation index of E2F7/8 
primary MEFs was evaluated by performing the growth curve assay (Figure 5a).  Detailed 
analyses of the in vitro proliferation rates revealed that the proliferation of E2f7-/-E2f8-/- cells 
were not impaired compared with wild type controls.  
To evaluate the apoptosis index, DKO were exposed to the DNA damaging drugs 
camptothecin and cisplatin.  Asynchronously proliferating wild type and conditional deleted 
DKO MEFs were treated for 18h with camptocethin.  The viability of the treated cells was 
determined by trypan blue exclusion at different time intervals post treatment. I found that 
camptocethin induced a significant acceleration of cell death in DKO MEFs compared to wild 
type MEFs (Figure 5b and 5c).  Furthermore, treatment with cisplatin triggered cleavage of 
Caspases-3 in E2f7-/-E2f8-/- MEFs, evaluated by Western blot analysis (Figure 5d).  These data 
indicate that loss of E2F7 and E2F8 results in increase sensitivity towards apoptosis in vitro.   
Depending on the cell type analyzed, the induction of apoptosis by deregulated E2F may 
be p53-dependent or independent (reviewed in Trimarchi and Lees, 2002; Bell and Ryan, 2004) 
Previous studies have shown that E2f1 can induce apoptosis in p53-dependent and p53-
independent manner. To further explore the mechanism of apoptosis triggered by the absence of 
E2F7 and E2F8, I confirmed the deregulation of E2F1 and p53 expression by Western blot 
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analysis (Figure 5e) and evaluated the expression of p53 target genes by real-time RT-PCR 
(Figure 5f).  DKO MEFs showed a marked increased expression of p53 targets compared to wild 
type cells.  Following camptocethin treatment, the levels of gene expression accelerated, in 
particular the levels of the p53 target genes, gadd45 and noxa were strongly elevated in DKO 
MEFS.  Taken together these findings suggest that E2F7 and E2F8 repress apoptosis by 
inhibiting the E2F1-p53 signaling pathway. 
 
Concomitant ablation of E2f7 and E2f8 in vivo has no effect on proliferation but induces 
E2F1-p53 dependent apoptosis  
Having in vitro data, the next question was whether the same phenotype will be observed in vivo 
under normal physiological conditions.  To assess whether loss of E2f7 and E2f8 influenced the 
level of proliferation occurring in vivo, I injected BrdU into pregnant females (1 or 3 hours 
before sacrifice) and measured BrdU incorporation immnunohistologically in serial sections.  As 
the representative pictures shown in Figure 8, there is no dramatic difference observed between 
DKO and wild type embryos.  
In contrast to our analysis of proliferation, I easily noticed comultifocal areas with 
abundant pyknotic and karyorrhectic nuclei which were present within the mesoderm, the 
branchial arch, the somites and the neural tube of DKO fetuses.  Consistently with these findings, 
these regions were preferentially labeled by the TdT-mediated dUTP nick end-labelling (TUNEL) 
assays, indicative of inappropriate apoptosis.  The frequency of apoptosis was three to five fold 
greater in DKO fetuses than in control siblings (Figure 7c).   
Based on the facts that induction of E2f1 and p53 was observed in E2f7-/-E2f8-/- MEFs, 
which are components previously associated with hypersensivity of cell death.  The hypothesis 
 17
then was that loss of E2f7 and E2f8 could lead to increase of apoptosis in an E2F1-p53 
dependent manner.  To test this hypothesis, I bred animals to either E2F1 or p53 mutant 
background.  If the massive apoptosis of the 78-deficient embryos were due to over expression of 
E2f1 and p53, the inactivation of E2f1 and p53 could reduce this apoptosis.  Analysis of E2f7+/-
E2f8+/-E2f1-/- or E2F7+/-E2f8+/-p53-/- embryos from triple mutant crosses revealed that 
inactivation of E2f1 or p53 clearly rescued the apoptosis phenotype of DKO embryos to normal 
status (Figure 7c).  However, these embryos still died at similar stage of gestation time like E2F7 
and E2F8 deficient embryos.  
 
E2F7 and E2F8 are required for angiogenesis  
To evaluate the possible cause of the intrauterine death of EfF7-/-E2f8-/- animals, I 
analyzed of haematoxylin- and eosin-stained sections obtained from wild-type and E2f7-/-E2f8-/- 
deficient placentas. Normally at around embryonic day 9-10, the allontois attaches to the 
chorionic plate, which is the initial step in the formation of a functional placenta, followed by 
vascular invasion of the labyrinth layer. The labyrinth is the site of oxygen and nutrient exchange 
between the mother and fetus, and consists of highly branched, trophoblast-covered maternal 
blood sinusoids in direct contact with the underlying fetal blood vessels. The wild-type labyrinth 
therefore has a porous appearance, with trophoblast cells being well organized and distributed 
around fetal and maternal blood vessels (Figure 9a). The fetal blood vessels contain nucleated 
erythrocytes invade and interdigitate into the labyrinth layer of the developing placenta.  
Placentas of viable DKO mutants were of normal size; however fetal blood vessels 
remain at the chorionic plate and did not efficiently invade into the labyrinth layer (Figure 9a). 
Maternal sinuses, containing mature nonnucleated erythrocytes, could be however readily 
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observed in the labyrinth. Vascular defects were also observed in the yolk sacs and in the embryo 
proper, characterized by large dilated and disorganized blood vessels with reduced branching of 
the vascular tree (Figure 9b). In addition starting at day E10.5, there was fluid extravasation in 
the pericardial cavity, as well as hemorrhages in the pericardium and the placenta of DKO 
animals. These findings suggest a defect in vascular differentiation with impaired angiogenic 
sprouting and remodeling in DKO mutants. These observations, however, will need to be 
confirmed by further analysis.  
 
Extra-embryonic function of E2F7 and E2F8 are essential for embryonic viability  
The physiological defects observed in E2f7-8 deficient animals had led me to examine the 
biological significance of E2f7 and E2f8 presence in placenta.  Harnessing the advantages of 
Cre-loxp transgenic system, I was able to selectively disrupt E2f7 and E2f8 in specific cell 
lineages.  I utilized E2f7loxP /loxPE2f8loxP /loxP conditional knockout mice and Sox2+/cre transgenic 
mice to reconstitute E2f7-8 deficient embryos with a functionally ‘wild-type’ placenta.  Previous 
studies had proven that using Cre-recombinase controlled by endogeneous Sox-2 promoter is 
sufficient to deliver functionally active Cre expression in all cells of embryo proper at E6.5 while 
producing little expression in the extra-embryonic compartment.  B-galactosidase staining of 
E12.5 and P0 animals including placenta derived from Sox2+/cre and Rosa26loxP/loxP reporter mice 
interbreedings verified the specific expression of Cre in fetal tissues as previously reported 
(Figure 10a)  
Interbreeding Sox2+/cre E2f7+/-E2f8+/- mice with E2f7loxP /loxPE2f8loxP /loxP mice was sufficient 
to reconstitute physiologically normal placentas to E2f7-8 deficient fetuses.  Yolk sac and 
placentas from all embryos were taken for PCR analyses to inquire genotypic segregation and to 
 19
detect deletion efficiencies in fetuses and placenta.   By Taking such genetic approach, I  could 
show that Sox2+/cre E2f7-/loxp E2f8-/loxp pups were born at birth according to Mendalian ratios 
(Table 4), indicating the vital function of E2f7 and E2f8 in extra-embryonic lineages for 
embryonic development.  To reconfirm that the loss of E2F7 and E2F8 in placenta is the 
compulsory event to produce mid-gestation death, I again took the advantages of Cre-loxP 
transgenic system recently established by Pam Wenzel and the Leone lab, which drives Cre-
recombinase expression under the control of human Cyp-19 promoter. I bred Cyp19+/cre E2f7loxp 
/loxpE2f8loxp/loxp mice to E2f7loxP /loxPE2f8loxP /loxP mice.  Such tissue specific promoter can target 
expression of Cre-recombinase to the placenta compartment of the embryo exclusively, and thus 
combining wild-type fetuses with E2f7 and E2f8 deficient placenta.  Cyp19+/cre E2f7loxp 
/loxpE2f8loxp/loxp embryos were developmentally retarded  (significantly smaller fetus size) at E9.5; 
they progressively began to demonstrate dilated vessels specifically in and around umbilical cord, 
mimicking the observed phenotype of E2f7 and E2f8 null embryos.  Finally, embryos of above 
genotype died and absorbed at E11.5 and no Cyp19+/cre E2f7loxp /loxp E2f8loxp /loxp embryos were 
found from that stage on (Table 5). This finding presented that disruption of E2f7 and E2f8 in 
extra-embryonic compartment alone can command lethality.  Furthermore, this suggests that the 
apoptotic and hemorrhaging phenotypes seen in the fetal tissues of E2f7-8 null embryos might 
have been a secondary result to the extra-embryonic pressure of losing E2f7 and E2f8.  
 
E2F7 and E2F8 can complex to Rb or its pocket proteins  
The resemblance of E2f7 and E2f8 deficient animals to Rb-null animals directed me to 
further explore the relationship between pRb and E2F7 or E2F8, to observe if there exits any 
physical interaction.   Due to the limitation of immunoprecipitation-quality antibody for both 
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E2F7 and E2F8, I utilized over-expression of plasmids containing epitope-tags to complete the 
co-immunoprecipitation procedures described here.  In a series of transfections and co-
immunoprecipitations, E2F7 was found to physically interacting to pRb, p130 and p107, detected 
by immunoblotting techniques (Figure 11a, 11c, 11e).  However, under a similar experimental 
design, E2F8 showed no detectable association with pRb, p130 and p107 (Figure 11b, 11d, 11f).  
Since it was shown that E2F7 and E2F8 can form hetero-dimer (Figure 3), it is conceivable that 
E2F8 might still be in complex with Rb through its binding to E2F7.  
I also explored that E2F7 and E2F8 might also be associated with other co-repressors 
with co-. Thus, I performed similar co-immunoprecipitations, transfecting epitope-tagged E2F7 
or E2F8 and differentially tagged co-repressor candidates, such as HDACs and Sin3s.  Upon co-
immunoprecipitation, I identified that E2F7 and E2F8 both present physical interactions to 
HDAC1 (Figure 12a and 12b) and Sin3a (Figure 12b and 12d). This finding supplemented the 
association of Rb to E2F7 and E2F8 in that E2F8 can complex to Rb through the association to 
E2F7 or the association to groups of co-repressors.  
 
Discussion  
The E2F7 and E2F8 transcription factors were the final members of the E2F family to be 
identified.  Here I show that unlike the function of other E2Fs, E2F7 and E2F8 are strictly 
required for embryonic development.  Their combined loss resulted in the accumulation of E2f1 
and p53, widespread apoptosis, vascular defects and embryonic death by E11.5.  The targeted 
inactivation of E2f1 or p53 suppressed the apoptosis in DKO embryos, suggesting that E2F7 and 
E2F8 control apoptosis via the E2F1-p53 axis.  The importance of E2F7 and E2F8 in embryonic 
development was shown to be specifically confined to the extra-embryonic cell lineages.  
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Phenotypes of developmental defects due to the ablation of E2f7 and E2f8 largely resembled the 
physiological responses to losing a closely related molecular partner, Rb, and this has led us to 
hypothesize that E2F7 and E2F8 are the direct mediator of Rb function.  
 
E2F7 and E2F8 constitute a distinct arm of the E2F network 
Because of the intense interest in E2Fs as major regulators of the cell cycle and apoptosis, 
individual E2F family members, including E2f1 through E2f6, have been extensively studied in 
vivo by gene targeting approaches in mice.  With the exception of E2f3 knockout mice, the 
specific defects that have been described for embryos deficient in each of the known E2Fs are 
rather subtle (Field et al., 1996; Yamasaki et al., 1996; Murga et al., 2001; Zhu et al., 2001).  
Disruption of the E2f3 gene in a mixed genetic background yields viable mice (Humboldt et al, 
2000; Wu et al 2001), whereas its disruption in pure strains results in embryonic lethality at 
around E12.5 (GL, unpublished observation).  It is surprising that embryos deficient for each of 
these E2Fs, even those deficient for E2f3, have no or little apparent defect in cellular 
proliferation and apoptosis.  This virtual absence of cell proliferation and apoptotic phenotypes 
in these knockout embryos has raised the possibility that E2Fs are either not critical for the 
control of proliferation and apoptosis in vivo or that there is sufficient functional redundancy 
among family members to accommodate for a deficiency in any single E2F. 
The role of E2F7 and E2F8 in mouse development was investigated here.  The targeted 
disruption of E2f7 and E2f8 had little consequence on development; however, their combined 
ablation resulted in widespread apoptosis, vascular defects and hemorrhaging, leading to 
embryonic death by E11.5.  Provision of even one functional allele from either loci was 
sufficient to carry fetuses through development all the way to birth.  E2F7 and E2F8 can form 
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homodimers and heterodimers.  Homodimerization of E2F8 when E2F7 is absent, and vice versa, 
may provide a molecular explanation for their functional redundancy during embryonic 
development.  
The contribution of E2F7 and E2F8, however, towards postnatal development does not 
appear to be equal.  Young and adult E2f7+/-E2f8-/- mice were of normal size and appeared 
developmentally normal, but most E2f7-/-E2f8+/- animals were runted and died within their first 
month of life (C.R. and J.L., unpublished results).  A bias in homo- versus hetero-dimerization 
may explain the differential requirement for E2f7 and E2f8 in adult development. I found that in 
tissue culture experiments at least, under conditions where expression levels can be compared 
(by epitope tagging) and experimentally equalized, the formation of E2F7:E2F7 homodimers 
was preferred over E2F7:E2F8 heterodimers; E2F8:E2F8 homodimers appeared to be the least 
preferred state (E2F7:E2F7 > E2F7:E2F8 >E2F8:E2F8).  While the molecular basis for homo- 
versus hetero-dimerization is not yet clear, these data suggest that inefficient homodimerization 
may compromise the ability of E2F8 to compensate for the loss of E2f7, an effect that might be 
aggravated in circumstances of limiting amounts of E2F8 (E2f7-/-E2f8+/-).  Thus, the observed 
bias for E2F7 homodimerization may explain the stricter postnatal requirement for this subunit.  
While this interpretation is likely an oversimplification, these results do provide a molecular 
explanation for their functional redundancy in development.  It will be interesting to investigate 
how dimerization might be impacted by the levels of E2F7 and E2F8 proteins in vivo or by 
tissue-specific signals. 
 
E2F7 and E2F8 regulate S-G2 specific expression of E2F-dependent genes. 
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E2F7 and E2F8 may have a particularly important role in repressing E2F-targets as cells transit 
through S phase.  Gene expression analysis in synchronized E2f7-/-E2f8-/- MEFs revealed that 
E2f1 mRNA levels, as well as that of many other E2F-target genes, increased acutely during S 
and G2.  This E2F7 and E2F8-mediated repression coincided with the time in the cell cycle at 
which E2f7 and E2f8 levels peak (de Bruin et al; Maiti et al).  Why the expression of E2F-targets 
need to be kept low during S and G2 is not entirely clear, but at least three mechanisms have 
evolved to achieve this.  One mechanism involves the binding of cyclin A/cdk2 to E2F1, E2F2 
and E2F3a during S phase, leading to the phosphorylation of the dimerization partner DP1/2 and 
the inhibition of E2F/DP DNA binding activity.  A second mechanism involves the Skp2/F-box-
dependent degradation of the three E2F activators during S phase (Leone et al, 1998).  Both the 
binding of cyclin A/cdk2 and the Skp2-dependent degradation of E2F activators require 
conserved domains within their N-termini.  Here I describe a third mechanism that involves 
E2F7- and E2F8-mediated repression of target genes that include the E2f1 and E2f3a genes 
themselves, ensuring that E2F-targets are kept at the lowest possible levels during S and G2.  
Thus, E2F7 and E2F8 appear to have a distinct role from the other E2F repressors (E2F3b, E2F4, 
E2F5 and E2F6), which play a more acute role in G0-G1, by participating in transcription 
repression during S-G2.  By directly regulating the expression of E2f1 and E2f3a, E2F7 and 
E2F8 couple S/G2 transitions to the control of G0/G1.   
 
E2F7 and E2F8 regulate apoptosis via the E2F1-p53 axis. 
In vitro and in vivo experiments described here provide clear-cut evidence in support of a role for 
E2F7 and E2F8 in the control of apoptosis.  The mechanism of their action involves, at least in 
part, the regulation of E2f1 expression.  ChIP experiments showed that E2F7 and E2F8 are 
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recruited to the E2f1 promoter.  Consistent with a role in repression of E2f1, genetic inactivation 
of E2f7 and E2f8 resulted in the accumulation of E2f1 mRNA and a corresponding increase in its 
protein product.  E2f1 promoter reporter assays indicated that the basis for the accumulation of 
E2f1 mRNA in E2f7-/-E2f8-/- cells likely involves a transcriptional mechanism.  Together, these 
results demonstrate a direct role for E2F7 and E2F8 in the repression of E2f1.   
The increase in E2f1 protein levels in E2f7-/-E2f8-/- cells coincided with the accumulation 
of p53 protein.  Several mechanisms of how E2F1 may lead to the accumulation and activation 
of p53 have been described.  For example, E2F1 overexpression has been shown to induce the 
expression of p19ARF .  A key function of p19ARF protein is to bind and sequester MDM2 to the 
nucleolus, and thereby prevent the MDM2-mediated degradation of p53 (Bates et al. 1998).  
E2F1 can also induce the expression of the ATM and CHK2 kinases, resulting in the 
phosphorylation, accumulation and activation of p53 (Russell et al. 2002; Rogoff et al. 2002).  
Moreover, E2F1 interacts directly with p53 via its N-terminal cyclin A binding domain, and this 
interaction enhances the apoptotic activity of p53 (Hsieh et al. 2002).  Hence, the accumulation 
of E2F1 protein can lead, via a number of mechanisms, to an increase of p53 protein and activity.  
The accumulation of E2F1 and p53 in E2f7-/-E2f8-/- cells is of physiological significance 
since ablation of either E2f1 or p53 suppressed the widespread apoptosis observed in DKO 
embryos.  Clearly, E2F7 and E2F8 are likely involved in repressing many more targets than just 
E2f1, and so it is not surprising that loss of E2f1 or p53 did not suppress the embryonic lethality 
phenotype.  These latter results suggest that apoptosis in E2f7-/-E2f8-/- embryos is not simply due 
to an indirect consequence of perturbed signaling associated with embryonic lethality, but rather 
a specific signal emanating from E2F1.  Consistent with this interpretation, the conditional 
ablation of E2f7 and E2f8 sensitized MEFs to apoptotic signals, suggesting that this susceptibility 
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involves a cell autonomous mechanism.  Together, these data show that E2F7 and E2F8 form an 
essential arm of the E2F network involved in the control of apoptosis via the E2F1-p53 axis. 
 
Functions and Characteristics of E2F7 and E2F8 revealed them as potential mediators of 
Rb  
The E2f7 and E2f8 genes are essential in maintaining normal in embryonic development; at least 
one functional allele is required for the viability of offspring fetuses.  E2f7 and E2f8 deficient 
embryos showed severe vasculature defects and ectopic apoptosis as a result to up-regulation of 
E2F1 and p53.  The phenotypic response to the simultaneous deletion of E2f7 and E2f8 during 
embryo development was significantly more severe than that found in of E2F knock-out models.  
These phenotypes were intriguingly similar to Rb-/- embryonic phenotype. Specifically the 
apoptotic phenotypes were in both cases via activation of E2F1 and p53 (de Bruin A.. et al, 
2003).  The ectopic E2F1 and p53 expression suggests that the regulation of apoptosis, at least 
under cytotoxic pressure, Rb and E2f7-8 are involved in the regulation of the E2f1-p53 axis 
(Harbour and Dean, 2000).   
Among other physiological defects of the mid-term lethality of E2f7 and E2f8 deficient 
embryos, E2f7 and E2f8’s biological function in constructing the placental-fetal interfaces was a 
particularly important event in ensuring embryonic survival.  Using Cre-loxP approaches to 
reconstitute functional placentas in E2f7-8 deficient embryos, I could show that the lethal 
phenotypes were suppressed allowing E2f7-8 deficient pups deliver at almost normal mendalian 
ratios.  Furthermore, specific ablation of E2f7 and E2f8 in extra-embryonic tissue could mimic 
the E2f7-/-E2f8-/- embryonic phenotypes including the early lethality, supporting the idea that loss 
of E2f7 and E2f8 in extra-embryonic lineages is the compulsory event for the observed lethality.  
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The finding was striking similarity to the extra-embryonic function of Rb in mid-stages of 
embryonic development (Wu et al, 2002).  Later in post-partum murine development, the 
physiological effect of losing E2f7 and E2f8 continues to resemble that of Rb. Specially, E2f7 
and E2f8 deficient animals that were delivered by supplying the wild-type placentas also 
encounter neonatal deaths. 
The speculation that E2F7 and E2F8 are potential mediators of Rb function was 
investigated by analyzing the possibility of physical interactions between Rb, its pocket proteins 
and E2f7 or E2f8.  I found that E2F7 was capable of binding to all three Rb family members to 
other know transcriptional co-repressors.  These binding activities could provide a reasonable 
explanation of the discrepancies that I observed between E2F7-8 mutant embryos and Rb mutant 
embryos (E2f7-/-E2f8-/- embryo died at E11.5 and Rb-/- died at E14.5), since p130 and p107 could 
potentially compensate for the loss of Rb.  E2F8 was found to be less tightly related to Rb, in 
which no direct association was found.  However, its recruitment to other co-repressors and its 
hetero dimer-partner E2F7 granted E2F8 the capacity to reside in the Rb-E2F7-E2F8 complex 
(data not shown).  
In summary, E2F7 and E2F8 are essential for embryonic development and may be 
viewed as a distinct arm of the E2F network that is involved in mediating Rb function.  I 
demonstrate that E2f1 represents a particularly critical target that if not tightly repressed by E2F7 
and E2F8 can elicit widespread apoptosis in developing embryos. 
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Figure 1. Schematic representations of E2F transcription factors. Eight distinct E2F gene loci encode 
for ten different E2F isoforms.  A conserved DNA binding domain (DBD) is the feature that distinguishes 
each isoform as a member of the E2F family of transcription factors. The N-terminal domain (NTD) of 
E2F1-3 harbors the cyclin A-binding and Skp-binding domains and is distinct from the NTD of E2F6-8. 
The leuzine zipper (LZ) domain common to E2F1-6 is involved in dimerizing with DP1 or DP2, but is 
absent in E2F7-8.  The Marked (Mark.) domain common to E2F1-6 is involved in mediating interactions 
with co-factors; The classical Rb binding (Rb bind.) domain buried within the activation domain is 
common to E2F1-5. 
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Figure 2. Generation of E2f7 and E2f8 knockout mice.  (a) Targeting strategies of E2f7 (left) and E2f8 (right) 
knockout mice.  Upper: partial exon/intron structures of the E2f7 and E2f8 genes.  The black bars under genomic 
sequence indicate the position of probes used for Southern analysis.  Middle: the targeting vectors, positions of TK 
and Neo (rectangle), as well as loxP sites (filled triangles) are indicated.  Bottom two: predicted conditional or 
conventional homologous recombination events. (b) Southern analysis of genomic DNA isolated from conventional 
knockout mice tails digested with Ase I for E2f7(left) and EcoR V for E2f8 (right) and hybridized using probes A or 
B, respectively (top).  Genotyping of tail DNA was performed using allele specific PCR primers described in 
Methods (bottom).  (c) Real-time RT-PCR analysis of E2f7 or E2f8 transcript using primers located in the knockout 
region.  Results are average ± SD of embryo cDNA samples in triplicate.  The genotypes are indicated at the 
bottom.
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TABLE 1: Genotypic analysis of embryos during development
E2f8+/+ E2f8-/-E2f8+/-
total
() number of dead embryos; Exact binomial test:  a significant (p<0.0015), b highly significant (p<0.0007).
E2f8+/+ E2f8-/-E2f8+/- E2f8+/+ E2f8-/-E2f8+/-
E2f7+/+ E2f7+/- E2f7-/-
Table 1. Genotypic analysis of E2f7 and E2f8 double knockout embryos survival at the indicated stages of 
development. 
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Figure 3. E2F7 and E2F8 homo- and hetero-dimerize and bind to E2f1 promoter.  (a) Lysates from HEK293 cells 
transfected with both flag-tagged and HA-tagged E2F7 and E2F8 were co-immunoprecipitated (IP) with anti-flag 
antibody and immunoblotted (IB) with anti-HA antibody or vice versa. Immunoprecipitation with normal mouse IgG 
was used as a negative IP control to rule out nonspecific bindings.  (b)  Upper panels: stable expression of flag-HA-
E2F7 in Hela cells.  After sorting, flag-HA-E2F7 transduced Hela cells were harvested and subjected to Western 
blot to test the ectopic E2F7 expression by using flag and HA specific antibodies.  Non-specific band from HA block 
was used as a loading control.  Bottom panels: E2F8 was identified from E2F7 complex purification.  Nuclear 
extracts from flag-HA-7 expressing cells were immunoprecipitated with flag antibody affinity resins.  Western blots 
were performed by using antibody against endogenous E2F8.  Mock-transduced Hela cells were used as a negative 
control.  (c) Binding preference of E2F7 and E2F8 was E2F7:E2F7> E2F7: E2F8 > E2F8 : E2F8.  Lyaste over-
expressing differentially tagged E2F7 and E2F8 was harvested post transfection. Immunoprecipitation of HA-tagged 
E2F7 (upper panel) and HA-tagged E2F8 (bottom panel) was detected by anti-myc antibody The intensity of signals 
was measured by densitometer. (d) E2F7 binds to the E2f1 promoter.  Chromatin from HEK293 cells 
overexpressing wild type flag-7 (wt) or flag-7DBD1,2 (mut) was immunoprecipitated with anti-flag antibody or normal 
mouse IgG control.  Chromatin immunoprecipitated DNA were specifically amplified by using primers flanking the 
E2f1 promoter region with the E2F binding sites, E2f1 exon1 region (control), and the tubulin promoter region.  Real-
time PCR was performed in triplicate and cycle numbers were normalized to the 1% input. (e) E2F7 and E2F8 
occupy the E2f1 promoter simultaneously.  HEK293 cells expressing ectopic HA-7 and flag-8 were used and 
sequential ChIP assay was performed as described in Methods.  DNAs collected after two rounds of chromatin 
immnuoprecipitations as indicated were subjected to real-time PCR analysis to assess the enrichment of the E2f1 
promoter.  The tubulin promoter was used as a negative promoter control. 
b8-
0-
2-Fo
ld
 in
du
ct
io
n 
in
 
ge
ne
 e
xp
re
ss
io
n
6-
4-
E2f1
E2f7+/+E2f8+/+
E2f7-/-E2f8-/-
E2f7+/+
E2f8+/+
E2f7-/-
E2f8-/-
Q 0 2 4 6 8 10 12
Hours post-HU release
Q 0 2 6 8 10 12
0 -
2 -
4 -
6 -
8 -
10 -
12 -
14 -
Fo
ld
 in
du
ct
io
n 
in
 g
en
e 
ex
pr
es
si
on
E2f7+/+E2f8+/+ E2f7-/-E2f8-/-
E2f1
Hours post-HU release
4
7+/+8+/+ 7-/-8-/-
E2F1
tubulin
a
e
c
5 -
10 -
15 -
20 -
25 -
30 -
R
el
at
iv
e 
lu
ci
fe
ra
se
ac
tiv
ity
E2f1 luc. reporter
0-
5 -
10 -
15 -
20 -
25 -
30 -
0-
E2f7+/+E2f8+/+
E2f7-/-E2f8-/-
wild type mutant
f
d
R
el
at
iv
e 
ge
ne
 e
xp
re
ss
io
n 1.2 -
0.8 -
0.4 -
0.0 -
+/+  -/-
+/+  -/-
+/+  -/-
+/+  -/-
:E2f7
:E2f8
E2f7 E2f8
+/+
-/-
E2f7 E2f8
Figure 4. E2f1 is a direct target of E2F7 and E2F8. (a) E2f7 and E2f8 expression in MEFs co-respond with 
their genotypic indication. Upper panel: PCR was performed from cell lysates to confirm the genotypic 
expression. Bottom panel: Q-PCR was performed to detection of E2f7 and E2f8 expression pattern.   (b) 
Western blot analysis of lysates from primary MEFs and their wild type littermate control.  Antibodies specific 
against E2F1 and p53 were used to test endogenous E2F1 and p53 protein level.  (c) Expression of E2f1 in 
the same MEFs cells were measured by real-time RT-PCR.  (d) Wild type and E2f7-/-E2f8-/- MEFs were 
transfected with indicated firefly luciferase reporter plasmids along with thymidine kinase renilla luciferase
construct (internal control).  Cells were forced into quiescence by serum withdrawal and restimulated with 
serum to allow cell cycle entry.  Cells were harvested at indicated time points and reporter activity was 
detected using dual luciferase assay system.  Reporter luciferase activity was normalized to renilla luciferase
and relative luciferase activity is shown in the graph.  (e) FACS analysis of MEFs with indicated genotypes.  
MEFs were synchronized by serum starvation and hydroxyurea (HU) block, and then released into the cell 
cycle.  As indicated time points, cells were harvested and stained by propidium iodide for flow cytometry.  Q: 
quiescence.  (f) Total RNAs were harvested at quiescence or indicated intervals following HU release and 
subjected to reverse transcription and real-time PCR to analyze relative RNA level of E2f1.  (g) Cell lysates 
were harvested at quiescence or indicated intervals following HU release and subjected to Western blot to 
analyze E2F1 protein level.  Tubulin was used as a loading control.
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Figure 5.  E2f7 and E2f8 deficient MEFs are hypersensitive to DNA damage induced apoptosis.  (a) 
E2f7-/-E2f8-/- has no defect in cellular proliferation.  Growth curve analysis of primary MEFs with the 
indicated genotypes.  (b) Camptothecin induces more cell death in E2f7 and E2f8 deficient MEFs. Wild 
type and E2f7-/-E2f8-/- MEFs were mock treated with DMSO (left) or 20μm camptothecin (right) for 
18h.  At the indicated intervals up to 120h, cells were harvested and viability was determined by trypan
blue exclusion.  (c) Light microscopy images of MEFs with indicated genotyping at 54h after 20μm 
camptothecin or mock treatment.  (d) Cisplatin triggers Caspase-3 activation in E2f7-/-E2f8-/- MEFs but 
not in the wild type control.  MEFs with indicated genotypes were treated with 10μm cisplatin for 24h.  
Lysates were analyzed at the indicated time points by Western blot for Caspase-3 cleavage.  (e) 
Western analysis of E2F1 and p53 proteins expression in the indicated cells after 18h and 24h of 20μm 
camptothecin treatment.  Tubulin was detected as an internal control.  (f) Total RNA was extracted from 
cells with indicated genotypes after 18h camptothecin treatment. Expression of indicated p53-target 
genes were measured by real-time RT-PCR.  Results are shown as fold induction in triplicate.
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Figure 6. E2f7 and E2f8 deficient embryos showed angiogenesis defect.  (a) Gross view of embryos at 
E9.5 and E10.5 days of embryonic development. Images were taken at 16x magnification using light 
microscope.  (b) HE staining of E9.5 embryos.
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Figure 7. E2f7 and E2f8 deficient embryos show increased apoptosis in vivo at E9.5. (a) Cell death of 
embryos with the indicated genotypes was assessed by TUNEL assay using 5μm formalin fixed paraffin 
sections.  Most left: low magnification pictures of the whole embryos.  Right three: high magnification 
pictures of the boxed areas from the low magnification pictures. (b) TUNEL staining of E2f1-/-E2f7-/-E2f8-/-
triple knockout embryos (top), and p53-/-E2f7-/-E2f8-/- triple knockout embryos (bottom).  (c) Quantification 
of apoptosis of the indicated tissue areas as determined by TUNEL assay. Results are average ± SD of 
the percentage of total number of cells that are TUNEL-positive.  At least 3 different embryos were 
counted for each genotyping group.
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Figure 8. Inactivation of E2f7 and E2f8 has no effect on proliferation in vivo at E9.5.  (a) BrdU staining of 
embryos with indicated genotypes. Most left: low magnification pictures of the whole embryos.  Right three: 
high magnification pictures of the boxed areas from the low magnification pictures.  (b) Proliferation 
indexes of different tissue areas with indicated genotypes were quantified by the percentage of total 
number of cells that are BrdU-positive.  
E9.5                    - 2                     5                    46
TABLE 2: Genotypic analysis of embryos during development
E2f1+/+ total
() number of dead embryos; Exact binomial test:  a highly significant (p<0.0007)
E2f7-/-E2f8-/- E2f7-/-E2f8-/-
E2f1+/- E2f1-/-
E2f7-/-E2f8-/-
E12.5                  - - 0(4)a 10
expected                   - 5                           6
expected                   - - 3
Table 2. Genotypic analysis of E2f1, E2f7 and E2f8 triple knockout embryos survival at the indicated 
stages of development. 
E9.5                    3                     6                 4                      66
TABLE 3: Genotypic analysis of embryos during development
p53+/+ total
() number of dead embryos; Exact binomial test:  a highly significant (p<0.0007).
E2f7-/-E2f8-/- E2f7-/-E2f8-/-
p53+/- p53-/-
E2f7-/-E2f8-/-
E12.5                  0                     0(1)               0(4)a 12
expected                   4                           8       4
expected                   1                           2       1
Table 3. Genotypic analysis of p53, E2f7; E2f8 Triple knock-out embryo survival at indicated stages of 
development.  
E2f7+/-
E2f8+/-
E2f7-/-
E2f8-/-
E10.5 placentasE9.5 placentas
E2f7+/-
E2f8+/-
E2f7-/-
E2f8-/-
a
b
Figure 9. Extra-embryonic function of E2f7 and E2f8 are essential for embryonic development. E2F7 and 
E2F8 disruption causes vascular defect in the labyrinth layer of the placenta. (a-b) placentas have 
marked defects in placental vascularization. (a) Hematoxylin and eosin staining of placentas of E10.5 
wild-type verse E2f7-/-E2f8-/- embryos. cp, chorionic plate; lb, labyrinth layer; m, maternal blood cells; f, 
fetal blood cells (nucleated). (b) Immunostaining for PECAM-1 (brown) on sections from E10.5 wild-type 
and E2F7 and E2F8 null placentas at E10.5. Faint nuclear counterstaining (blue) was achieved with 
Meyer's hematoxylin. 
TABLE 4: Genotypic analysis of embryos during development: Sox2-Cre Deletion
total E2f8-/loxp E2f8+/loxp
E10.5    28 4            -- 5           -- 4 -- 5 --
E12.5    27            1            -- 7            -- 2           -- 4          --
P0         33            3            4              6          5                  3           6                 3           3
E2f8-/loxp E2f8+/loxp
E2f7-/loxp E2f7+/loxp
E2f8-/loxp E2f8+/loxp
CreE2f7-/loxp CreE2f7+/loxp
expected 3                -- 3                -- 3                 -- 3                --
expected                          3                 -- 3                  -- 3                -- 3              --
expected                          4                  4         4                 4                         4        4                        4                4  
E2f8-/loxp E2f8+/loxp
Table 4. Genotypic analysis of genetic rescue from interbreeding Sox-2 Cre animals to E2f7 E2f8
conventional deletion animals
TABLE 5: Genotypic analysis of embryos during development: Cyp19-Cre Deletion
total
() number of dead embryos; Exact binomial test:  a significant (p<0.05).
E2f8-/loxp E2f8+/loxp
E10.5    13 2            1 0            1                 0(3)a -- 1 5
E12.5    20            4            3               5           1                 0(2)a 3                 1           3
E2f8-/loxp E2f8+/loxp
E2f7-/loxp E2f7+/loxp
E2f8-/loxp E2f8+/loxp
CreE2f7-/loxp CreE2f7+/loxp
expected 1                 1                      1               2 1                 1                    1                1 
expected                          2                  2        2                 2                         2      2                        2                 2
E2f8-/loxp E2f8+/loxp
Table 5. Genotypic analysis of genetic rescue from interbreeding Cyp-19 Cre animals to E2f7 E2f8
conventional deletion animals.
a 
b
Rosa26loxp/loxp; E2f7loxp/loxp; E2f8loxp/loxp
Sox-2+/+ Sox-2+/Cre  Neonate Sox-2+/Cre  placenta
Fetus Placenta
Rosa26loxp/loxp; E2f7loxp/loxp; E2f8loxp/loxp
Cyp19+/cre
Cyp19+/cre
Cyp19+/+
Figure 10. Endogenous promoter Sox-2 and Cyp-19 can direct specific Cre-recombinase expression in desired 
tissue types. (a) B-galactosidase analysis of Sox-2+/Cre E2f7loxp/loxp E2f8loxp/loxp P0 neonates and its placenta in 
comparison to wild-type neonates.  (b) B-galactosidase analysis of Sox-2+/Cre E2f7loxp/loxp E2f8loxp/loxp E12.5 
fetuses and their placenta in comparison to wild-type embryos.   Enzyme activity will be detected when a dark 
blue color is observed, which in turn represents the presence of cre expression. 
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Figure 11.  E2F7 and E2F8 associate with Rb and its pocket protein.. Lysates from HEK293 cells transfected 
with indicated epitope-tagged plasmid were co-immunoprecipitated (IP) with anti-flag antibody and immunoblotted 
(IB) with anti-myc or anti-HA antibodies.  Immunoprecipitation with normal mouse IgG was used as an internal 
negative control to rule out non-specific bindings (a) Flag-tagged E2f7 and myc-tagged Rb (b) Flag-tagged E2f8 
and myc-tagged Rb (c) Flag-tagged E2f7 and HA-tagged p130  (d) Flag-tagged E2f8 and HA-tagged p130  (e)
Flag-tagged E2f7 and HA-tagged p107  (f) Flag-tagged E2f7 and HA-tagged p107. All results indicating physical 
interaction between E2f7 and Rb or its family pocket proteins, but E2F8 fails to show bindings with all three 
protein in over-expression. 
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Figure 12.  E2F7 and E2F8 can recruit corepressors.  Lysates over-expressing (a) Flag-tagged 
HDAC1 and HA- tagged E2F7; (b) Flag-tagged HDAC1 and HA- tagged E2F8; (c) Flag-tagged 
E2F7 and myc-tagged Sin3a; (d) Flag-tagged E2F8 and myc-tagged Sin3a were used in co-
immunoprecipitation using anti-flag antibody and immunoblotted with anti-HA or anti- myc
antibodies.  Physical associations were seen among all proteins.
